Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618895 | 0.93 | BTK (0.50) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL23366831 | 0.93 | EPHX1 (0.51) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL923552 | 0.91 | EPHX1 (0.54) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL23366889 | 0.89 | KMT2A (0.45) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL27799448 | 0.89 | KMT2A (0.45) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL8267426 | 0.85 | KMT2A (0.51) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL23367237 | 0.82 | KMT2A (0.43) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL29873938 | 0.82 | KMT2A (0.43) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL28747565 | 0.82 | KMT2A (0.55) | KMT2AMEN1ALDH1A1TSHREPHX1 | |
| SCHEMBL23366924 | 0.82 | KMT2A (0.42) | KMT2AMEN1ALDH1A1TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2014066151-A1 | AGGRECANASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2651895-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | KMT2A 697/4885MEN1 2833/4885ALDH1A1 244/4885 |
| US-20230027985-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAMTS1 | KMT2A 3100/4885MEN1 2636/4885ALDH1A1 2009/4885 |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | ADAMTS7, MMP7, ADAM17 | KMT2A 3535/4885MEN1 2481/4885ALDH1A1 3828/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | KMT2A 963/4885MEN1 4744/4885ALDH1A1 780/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | KMT2A 697/4885MEN1 2833/4885ALDH1A1 244/4885 |
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | KMT2A 1739/4885MEN1 1367/4885ALDH1A1 202/4885 |
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | KMT2A 3535/4885MEN1 2481/4885ALDH1A1 3828/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | KMT2A 697/4885MEN1 2833/4885ALDH1A1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.